Advertisement

Advertisement

OTLK Stock Latest News

Outlook Therapeutics Announces New Equity Financing Transaction

Company AnnouncementsOutlook Therapeutics Announces New Equity Financing Transaction

Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering

PremiumThe Fly

Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering

9d ago

Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug

PremiumCompany Announcements

Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug

10d ago

Outlook Therapeutics completes Federal Dispute Resolution meeting with FDA

PremiumThe Fly

Outlook Therapeutics completes Federal Dispute Resolution meeting with FDA

10d ago

Regulatory Uncertainty and Data Limitations Justify Hold Rating and Constrained Upside for Outlook Therapeutics

PremiumRatings

Regulatory Uncertainty and Data Limitations Justify Hold Rating and Constrained Upside for Outlook Therapeutics

23d ago

Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010

PremiumCompany AnnouncementsOutlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010

24d ago

Outlook Therapeutics submits formal dispute resolution request to FDA

The Fly

Outlook Therapeutics submits formal dispute resolution request to FDA

24d ago

Outlook Therapeutics Completes Dilutive Equity Offering With Warrants

Company Announcements

Outlook Therapeutics Completes Dilutive Equity Offering With Warrants

1M ago

Outlook Therapeutics announces common stock, warrant offering, no amount given

PremiumThe Fly

Outlook Therapeutics announces common stock, warrant offering, no amount given

1M ago

Outlook Therapeutics Refinances Debt, Extends Note Maturities

PremiumCompany Announcements

Outlook Therapeutics Refinances Debt, Extends Note Maturities

2M ago

Outlook Therapeutics announces $18.4M non-convertible note financing

PremiumThe Fly

Outlook Therapeutics announces $18.4M non-convertible note financing

2M ago

Outlook Therapeutics Announces Board Resignation and Size Reduction

PremiumCompany Announcements

Outlook Therapeutics Announces Board Resignation and Size Reduction

2M ago

Outlook Therapeutics price target lowered to $6 from $10 at Ascendiant

PremiumThe FlyOutlook Therapeutics price target lowered to $6 from $10 at Ascendiant

2M ago

Outlook Therapeutics Shareholders Back Board, Pay, and Auditor

Company Announcements

Outlook Therapeutics Shareholders Back Board, Pay, and Auditor

2M ago

Outlook Therapeutics advances FDA dialogue on ONS-5010 approval

Company Announcements

Outlook Therapeutics advances FDA dialogue on ONS-5010 approval

2M ago

Outlook Therapeutics provides update following FDA meeting on ONS-5010

PremiumThe Fly

Outlook Therapeutics provides update following FDA meeting on ONS-5010

2M ago

Outlook enters distribution agreement for sale of Lytenava in Switzerland

PremiumThe Fly

Outlook enters distribution agreement for sale of Lytenava in Switzerland

2M ago

Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance

PremiumCompany Announcements

Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance

2M ago

Neutral Outlook Maintained Amid Slower Lytenava Ramp and Heightened U.S. Regulatory and Market Risks for ONS-5010

PremiumRatings

Neutral Outlook Maintained Amid Slower Lytenava Ramp and Heightened U.S. Regulatory and Market Risks for ONS-5010

2M ago

Outlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)

PremiumThe FlyOutlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)

2M ago

Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA

Company Announcements

Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA

3M ago

Outlook Therapeutics sumbits Type A meeting request to FDA

The Fly

Outlook Therapeutics sumbits Type A meeting request to FDA

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >